Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer

NEXT STORY
Company Announcement Oncology Venture Publishes Q1 2020 Report for the Period January – March 2020
PREV STORY
Onxeo Announces Approval of the REVocan Study by Regulatory Authorities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunomedics Issues Statement to Stockholders and Files Investor Presentation

Highlights New, Independent Board Focused on Maximizing Stockholder Value at Critical Near-Term Value-Inflection PointUrges ...

author_avatar
NASDAQ Market News

Esoteric Testing Market will retain 9.4% CAGR to beat $35 billion by 2024: Global Market Insights, Inc.

Esoteric testing Market Size By Test Type, By Technology and Regional Outlook (U.S., Canada, ...

author_avatar
NASDAQ Market News

Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO

NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused ...

author_avatar
NASDAQ Market News